Form 4: Zeo ScientifiX CMO Receives Stock Option Grant

Chief Medical Officer George Craig Shapiro was granted 1.25 million stock options in Zeo ScientifiX, Inc.

Summary

• George Craig Shapiro, Chief Medical Officer of Zeo ScientifiX, Inc., received a grant of 1,250,000 stock options on June 10, 2026.
• The grant is split into two equal tranches of 625,000 options each, both with an exercise price of $1.67 per share.
• The first tranche of 625,000 options vested immediately upon the grant date.
• The second tranche of 625,000 options is subject to performance-based vesting milestones.
• All options have a ten-year term expiring on June 10, 2036, and are exercisable on a cashless basis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices, with the only notable aspect being the specific anti-dilutive protection for the executive.

Positives

• Aligns the interests of the Chief Medical Officer with long-term shareholder value through equity-based compensation.
• Includes performance-based vesting for half of the grant, incentivizing the achievement of specific corporate milestones.

Negatives

• The immediate vesting of 625,000 options provides no retention incentive for the first half of the grant.
• The inclusion of anti-dilutive provisions for the performance-based options may protect the executive at the expense of existing shareholders in future capital raises.

Risks

• Potential dilution of existing shareholders upon the exercise of the 1,250,000 options.
• Anti-dilutive clauses could complicate future equity financing structures.

Future Outlook

The company intends to utilize performance-based milestones to drive future growth, as evidenced by the vesting conditions attached to the second tranche of options.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology and life sciences sector are standard practice for talent retention and alignment, though the inclusion of specific anti-dilutive clauses is a more aggressive protective measure for the executive.

Comparison to Industry Standards

• The use of the 2021 Equity Incentive Plan is consistent with standard corporate governance practices for small-cap biotech firms.
• Cashless exercise provisions are common in executive compensation packages to facilitate liquidity without requiring immediate capital outlay from the executive.

Corporate Governance

Stakeholder Impact

• Shareholders may face potential dilution if these options are exercised.
• The CMO is now more directly incentivized to meet performance targets.

Next Steps

• Achievement of performance milestones for the vesting of the second tranche of 625,000 options.
• Potential future exercise of options by the reporting person.

Key Dates

Keywords

Zeo ScientifiX, ZEOX, Stock Options, Executive Compensation, Form 4, Insider Transaction